Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: A retrospective data analysis
Archives of Psychiatric Nursing · 2025-02 · 54 · 26-30
DOI: 10.1016/j.apnu.2024.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Psychiatric Nursing, 2025-02. Verfasst von Jingyuan Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The Fourth People's Hospital of Wuhu, Wuhu 241000, Anhui Province, China. Electronic address: Lijingyuan99@163.com. Hauptthemen laut MEDLINE: Olanzapine, Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study aimed to comprehensively evaluate the efficacy and safety of olanzapine in the treatment of individuals with schizophrenia. METHODS: A retrospective study was conducted on 150 individuals with schizophrenia treated with olanzapine at a tertiary psychiatric hospital from January 2015 to December 2020. The efficacy was assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP) scale, and Brief Psychiatric Rating Scale (BPRS). Safety was evaluated based on the incidence of adverse events. Data were analyzed using descriptive statistics, paired t-tests, chi-square tests, and multiple regression analysis. RESULTS: The mean PANSS total score significantly decreased from 92.3 ± 13.8 at baseline to 56.9 ± 11.5 after 12 weeks of treatment (p < 0.001). Significant improvements were observed in positive symptoms, negative symptoms, and general psychopathology subscales (p < 0.001). CGI-S, PSP, and BPRS scores also demonstrated significant enhancements in overall clinical status, social functioning, and psychiatric symptoms (p < 0.001). The most common adverse events were weight gain (28 %), somnolence (22 %), dizziness (18 %), and dry mouth (15 %). Mild elevations in metabolic parameters were observed. The incidence of EPS was low (6 %), and prolactin levels increased mildly. Higher baseline symptom severity and younger age as predictors of greater improvement in PANSS scores (p < 0.01). CONCLUSIONS: Olanzapine demonstrated significant efficacy in reducing a wide range of schizophrenia symptoms, improving clinical status, enhancing social functioning, and alleviating overall psychiatric symptoms. The safety profile was generally manageable, with mild to moderate adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, The Fourth People's Hospital of Wuhu, Wuhu 241000, Anhui Province, China. Electronic address: Lijingyuan99@163.com.
- Department of Psychiatry, The Fourth People's Hospital of Wuhu, Wuhu 241000, Anhui Province, China. Electronic address: Ffyuchen@hotmail.com.
Zitieren
APA
Li, J., & Chen, F. (2025). Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: A retrospective data analysis. Archives of Psychiatric Nursing, 54, 26-30. https://doi.org/10.1016/j.apnu.2024.12.005
Vancouver
Li J, Chen F. Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: A retrospective data analysis. Archives of Psychiatric Nursing. 2025;54:26-30. doi:10.1016/j.apnu.2024.12.005
BibTeX
@article{Li2025,
author = {Li, Jingyuan and Chen, Fangyu},
title = {Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: A retrospective data analysis},
journal = {Archives of Psychiatric Nursing},
year = {2025},
volume = {54},
pages = {26--30},
doi = {10.1016/j.apnu.2024.12.005}
}
EUVIMED